Home 
Today's Top Picks 
Top Performers 
Watchlist 
My Robo Portfolios 
ETF Zone 
How It Works 
News - Chart
- Upturn Summary
- Highlights
- Revenue
- Valuation
Upturn AI Summary - About
Pacific Biosciences of California(PACB)
Advisory History & Simulated Performance *
*as per simulation (see disclosures)- ALL
- 1Y
- 1M
- 1W
- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- PASS (Skip)
Stock price based on last close Advisory Performance History (Simulated)
Upturn Advisory & Investor View for PACB
10/26/2026: PACB (1-star) is currently NOT-A-BUY. Pass it for now.
Pacific Biosciences is a life sciences tools company known for its high-accuracy long-read DNA and RNA sequencing technology. The company’s core growth opportunity lies in the widespread adoption of its Revio platform, which aims to provide affordable, large-scale genomic data for clinical and research applications. Despite this potential, investors face risks, including consistent operating losses, high cash burn, and intense competition from industry incumbents like Illumina. The stock is best suited for growth-oriented investors with a high risk tolerance who are monitoring the company's ability to achieve long-term profitability. Its future performance will likely hinge on continued system adoption and the successful expansion of its portfolio into broader clinical markets.
How to Read the Upturn Advisory
The Upturn Star Rating and the current BUY, SELL, or PASS advisory are generated by Upturn’s AI advisory engine based on proprietary signal analysis, price behavior, advisory history, and historical signal performance.
Company fundamentals, valuation, risks, and news provide supporting context about the business.
Investor Fit
| Investor style | Fit | Why |
|---|---|---|
| Growth investor | Strong fit | PacBio offers high-growth potential driven by its proprietary long-read sequencing technology in a expanding genomics market. |
| Momentum investor | Mixed fit | Momentum fit is conditional on positive technical price trends and sustained adoption of the Revio system. |
| Value investor | Weak fit | The company is not currently profitable, making it a poor fit for traditional value-based investment strategies. |
| Dividend investor | Weak fit | Pacific Biosciences does not pay a dividend as it focuses entirely on reinvestment for growth. |
| Low-risk investor | Weak fit | High volatility and the risks associated with an emerging growth biotech company make this unsuitable for low-risk portfolios. |
Risk Profile
| Risk factor | Level | Why it matters |
|---|---|---|
| Price volatility | High | The stock is subject to significant swings based on clinical research funding and technology adoption cycles. |
| Valuation risk | Medium / high | Valuations are highly sensitive to future revenue growth projections which are subject to execution risk. |
| Competition risk (sequencing incumbents) | High | The company faces intense competition from well-funded rivals like Illumina and Oxford Nanopore. |
| Business quality | Medium | While the technology is advanced, the company is still scaling toward consistent profitability and cash generation. |
| Dividend income | Low / none | The company does not provide income through dividends. |
| Execution risk | Medium / high | Success depends on the company's ability to manufacture, market, and support its complex sequencing systems at scale. |
Price Behavior
Flat / Range-Bound
The stock price has been trading within a narrow range with minimal directional movement.
Highly Choppy
The stock has experienced frequent, large price swings that make its near-term movement less predictable.
Analysis of Past Performance
Type Stock | Historic Profit -66.18% | Avg. Invested days 15 | Today’s Advisory PASS |
Upturn Advisory Rating  | Upturn Advisory Performance  1.0 | Stock Returns Performance  1.0 |
| Profits based on simulation | Last Close 10/26/2026 |
Upturn Scorecard
Upturn Star Rating 
Company Fundamentals
Financial Health Rating
Growth Momentum Score
Ownership
Top 5 Institutional Investors
Unit Economics (Per $1K Revenue)
Economic Dimensions
Quantitative Style Profile
Style Classification
Quality Focused
Key Highlights
Company Size Small-Cap Stock | Market Capitalization 655.85M USD | Price to earnings Ratio - | 1Y Target Price 2.54 |
Price to earnings Ratio - | 1Y Target Price 2.54 | ||
Volume (30-day avg) 16.2M shares | Beta 2.19 | 52 Weeks Range 1.07 - 3.44 | Updated Date 10/25/2026 |
52 Weeks Range 1.07 - 3.44 | Updated Date 10/25/2026 | ||
Dividends yield (FY) - | Basic EPS (TTM) -0.43 |
How Company Makes Money
| Business area | What it includes | Retail investor read |
|---|---|---|
| Sequencing Instruments | Sales of Revio and other genomic sequencing platforms to research and clinical labs. | The company sells expensive high-tech scientific machinery. |
| Consumables & Services | Recurring sales of SMRT cells, reagent kits, and equipment maintenance contracts. | They generate steady, repeatable revenue from existing customers using their machines. |
Analyzing Revenue: Products, Geography and Growth
Revenue by Products
Product revenue - Year on Year
Revenue by Geography
Geography revenue - Year on Year
Valuation
Trailing PE - | Forward PE - | Enterprise Value 885.77M | Price to Sales(TTM) 4.12 |
Enterprise Value 885.77M | Price to Sales(TTM) 4.12 | ||
Enterprise Value to Revenue 5.56 | Enterprise Value to EBITDA 140.79 | Shares Outstanding 310.83M | Shares Floating 304.17M |
Shares Outstanding 310.83M | Shares Floating 304.17M | ||
Percent Insiders 8.86 | Percent Institutions 56.97 |
Financial Metrics
🧭 Investment Snapshot
Total Revenue (Scale)
Total money earned from selling products or services before any costs. It is needed to understand the scale of the business and its ability to generate income.
Net Income (Profit)
Final profit after all expenses, interest, and taxes are deducted. It is needed to determine the overall profitability available to shareholders.
Free Cash Flow (Cash Strength)
Cash remaining after operating activities and capital expenditures, showing cash available for growth. It is needed to evaluate the company’s ability to invest, pay dividends, or reduce debt.
📈 Growth & Strength
Operating Income (Core Profit)
Profit from core operations after deducting all operating expenses. It is needed to measure how efficiently the company runs its primary business activities.
EBITDA (Cash Earnings)
Earnings before interest, taxes, depreciation, and amortization, indicating operating cash potential. It is needed to compare operating performance across companies without accounting or financing differences.
Gross Profit (Unit Profitability)
Revenue minus cost of revenue, showing profit after direct production costs. It is needed to evaluate core business profitability before overhead expenses.
🛡️ Financial Safety
Cash (Liquidity Buffer)
Total cash and cash equivalents on hand. It is needed to evaluate immediate liquidity and financial flexibility.
Total Debt (Leverage Risk)
Total debt including both short-term and long-term components. It is needed to assess the company’s leverage and financial risk.
Net Working Capital (Short-Term Health)
Current assets minus current liabilities, indicating short-term liquidity strength. It is needed to assess whether the company can meet its short-term obligations.
🧱 Balance Sheet Strength
Stockholder Equity (Net Worth)
Total equity value held by shareholders. It is needed to understand the net worth of the company from the owners’ perspective.
Total Assets (Asset Base)
The full value of everything the company owns, including cash, inventory, equipment, and investments. It is needed to understand the resource base used to generate revenue.
Income Before Tax (Pre-Tax Earnings)
Income before provision for income taxes. It is needed to analyze profitability independent of tax structures.
⚙️ Cost & Drag Factors
Cost of Revenue (Production Cost)
Direct costs required to produce and deliver the products or services sold. It is needed to assess efficiency in production and service delivery.
Total Operating Expenses (Operating Cost)
Indirect costs of running the business such as salaries, marketing, and administration. It is needed to understand how much it costs to sustain ongoing business operations.
Income Tax Expense (Tax Drag)
Amount of taxes paid or payable to the government. It is needed to evaluate the impact of taxation on overall profitability.
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.
All company names, trademarks, logos, and brands are the property of their respective owners and are used for identification and informational purposes only. Use of these names, trademarks, and logos does not imply endorsement by their respective owners.